Well, for those patients who have been fortunate enough to have taken the drug, they are still alive. Their odds of that without the drug after having failed all other therapy is close to zero. The abstract was written some months ago so the survival is actually 2-3 time the SOC. The first patient was enrolled nearly a year ago.
You are free to short the stock,and diss it all you want.
I hold a core position and a trading position. My core shares are all free riding now. Coming into ASCO, my trading shares will likely make me a good amount of money again.
You do it your way, I'll do it mine, and I'll hope the drug is successful so that many more can survive the very deadly glioblastoma.
News 
Market Data 
Discover 
AI
